Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : CVTX - CV Therapeutics, Inc. -- Ignore unavailable to you. Want to Upgrade?

To: tuck who wrote (232)	10/25/2005 4:19:18 PM
From: tuck	Read Replies (1) \| Respond to of 411

[Withdraws ranolazine MAA in Europe, will resubmit with PK studies] This may hurt a bit. >>PALO ALTO, Calif., Oct. 25 /PRNewswire-FirstCall/ -- CV Therapeutics, Inc. (Nasdaq: CVTX - News) announced today that the European Medicines Agency (EMEA) has indicated that additional clinical pharmacokinetic information would be needed prior to potential approval of ranolazine in Europe for the treatment of chronic angina. At this point in the process, the European centralized regulatory procedure does not provide a mechanism for obtaining and adding new information to a marketing authorization application (MAA). Accordingly, the company has withdrawn its MAA for ranolazine in Europe, and anticipates resubmitting it at a later date. Based on dialogue to date with the EMEA, the company expects one or more additional clinical pharmacokinetic studies will be required prior to any approval, but does not expect that a large or lengthy clinical trial would be required. The company plans to continue working with the EMEA to further clarify the next steps to support the potential resubmission and approval of ranolazine in Europe and has not determined a target date for resubmission of an MAA. In the United States, an amended new drug application (NDA) for ranolazine for the treatment of chronic angina in a restricted patient population is currently under review by the U.S. Food and Drug Administration (FDA). This amended NDA includes the results of the ERICA study, which was conducted under the FDA's special protocol assessment (SPA) process. The NDA amendment was submitted as a complete response to an October 2003 approvable letter, and the Prescription Drug User Fee Act date for FDA action on the NDA is January 27, 2006. The SPA agreement is an agreement between CV Therapeutics and the FDA and does not apply to European regulatory authorities.<< snip Cheers, Tuck